Key points are not available for this paper at this time.
Dysregulation of BLyS over extended periods of time is common in patients with SLE. Neutralization of BLyS activity with an appropriate BLyS antagonist may be therapeutically beneficial.
Stohl et al. (Mon,) studied this question.